Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
11 Cards in this Set
- Front
- Back
|
Heroin has high lipid solubility, crosses the blood-brain barrier quickly, and is deacetylated to
|
active metabolites 6-monoacetyl morphine and morphine.
|
|
|
Heroin has high lipid solubility, crosses the blood-brain barrier quickly, and is deacetylated to
|
active metabolites 6-monoacetyl morphine and morphine.
|
|
|
Heroin has high lipid solubility, crosses the blood-brain barrier quickly, and is deacetylated to
|
active metabolites 6-monoacetyl morphine and morphine.
|
|
|
The opioid-withdrawal syndrome (Table 23-7) is very unpleasant but not life threatening. It begins within
|
6 to 12 hours after the last dose of a short-acting opioid and as long as 72 to 84 hours after a very long-acting opioid medication.
|
|
|
The opioid-withdrawal syndrome (Table 23-7) is very unpleasant but not life threatening. It begins within
|
6 to 12 hours after the last dose of a short-acting opioid and as long as 72 to 84 hours after a very long-acting opioid medication.
|
|
|
Heroin withdrawal is brief (5 to 10 days) and intense.
|
Heroin withdrawal is brief (5 to 10 days) and intense.
|
|
|
Heroin withdrawal is brief (5 to 10 days) and intense.
|
Heroin withdrawal is brief (5 to 10 days) and intense.
|
|
|
Heroin withdrawal is brief (5 to 10 days) and intense.
|
Heroin withdrawal is brief (5 to 10 days) and intense.
|
|
|
any of the autonomic symptoms of opioid withdrawal such as nausea, vomiting, cramps, sweating, tachycardia, and hypertension result from the loss of opioid suppression of
|
the locus ceruleus system during the abstinence syndrome. Clonidine, acting via distinct receptors but by cellular mechanisms that mimic opioid effects, can alleviate many of the symptoms of opioid withdrawal. However, clonidine does not alleviate generalized aches and opioid craving characteristic of opioid withdrawal. When using clonidine to treat withdrawal, the dose must be titrated according to the stage and severity of withdrawal, beginning with 0.2 mg orally. Postural hypotension commonly occurs when clonidine treatment is used for withdrawal. A similar drug, lofexidine (not yet available in the United States), has greater selectivity for α2A adrenergic receptors and is associated with less of the hypotension that limits the usefulness of clonidine in this setting.
|
|
|
any of the autonomic symptoms of opioid withdrawal such as nausea, vomiting, cramps, sweating, tachycardia, and hypertension result from the loss of opioid suppression of
|
the locus ceruleus system during the abstinence syndrome. Clonidine, acting via distinct receptors but by cellular mechanisms that mimic opioid effects, can alleviate many of the symptoms of opioid withdrawal. However, clonidine does not alleviate generalized aches and opioid craving characteristic of opioid withdrawal. When using clonidine to treat withdrawal, the dose must be titrated according to the stage and severity of withdrawal, beginning with 0.2 mg orally. Postural hypotension commonly occurs when clonidine treatment is used for withdrawal. A similar drug, lofexidine (not yet available in the United States), has greater selectivity for α2A adrenergic receptors and is associated with less of the hypotension that limits the usefulness of clonidine in this setting.
|
|
|
any of the autonomic symptoms of opioid withdrawal such as nausea, vomiting, cramps, sweating, tachycardia, and hypertension result from the loss of opioid suppression of
|
the locus ceruleus system during the abstinence syndrome. Clonidine, acting via distinct receptors but by cellular mechanisms that mimic opioid effects, can alleviate many of the symptoms of opioid withdrawal. However, clonidine does not alleviate generalized aches and opioid craving characteristic of opioid withdrawal. When using clonidine to treat withdrawal, the dose must be titrated according to the stage and severity of withdrawal, beginning with 0.2 mg orally. Postural hypotension commonly occurs when clonidine treatment is used for withdrawal. A similar drug, lofexidine (not yet available in the United States), has greater selectivity for α2A adrenergic receptors and is associated with less of the hypotension that limits the usefulness of clonidine in this setting.
|
